Every 10-Q that Gaxos.ai Inc. (GXAI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GXAI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GXAI filings page.
Gaxos.AI Inc. reported sharply higher revenues and a strategic portfolio shift for the quarter ended June 30, 2026. Revenue rose to $2,457,357 from $170,971 a year earlier, driven mainly by RNK Health administrative services and subscriptions from Gaxos Labs products such as Art-Gen.ai, UnGPT.ai and Bible Pray AI.
Operating expenses increased significantly as the company scaled, with research and development at $506,971 and selling, general and administrative at $3,815,141, largely from marketing RNK Health and subscription apps. This produced an operating loss of $1,864,755, but a $1,749,890 gain on the sale of gaming assets and investment income led to net income attributable to common shareholders of $241,056 for the quarter.
The company sold substantially all gaming assets to Game Foundry AI for shares valued at $1,760,000 and separately invested $200,000 in Game Foundry, while also acquiring a 19.99% stake in America First Defense.AI for $2,915,000. Liquidity remains solid with cash of $1,089,449, short-term investments of $10,353,040 and working capital of $10,769,048. Shares outstanding increased to 10,744,634 following ATM equity sales.
Gaxos.AI Inc. filed an amendment to its quarterly report for the period ended March 31, 2026 to correct the common share count disclosed in its officer certifications. The number of shares of common stock outstanding as of May 13, 2026 is stated as 10,219,934.
The amendment is limited to revising the Section 302 certifications (Exhibits 31.1 and 31.2), changing the share figure from 7,123,453 to 10,219,934 and omitting paragraph 3 because no financial statements are included. All other disclosures in the original quarterly report remain unchanged.
Gaxos.AI Inc. reported sharp early-stage growth alongside wider losses for the quarter ended March 31, 2026. Revenue rose to $1,809,367 from $23,732 a year earlier, driven mainly by $1,245,909 of administrative services from RNK Health and $563,458 of subscription revenue from its AI applications.
Operating expenses increased to $4,356,489, led by $2,766,824 of advertising and marketing, pushing net loss to $2,474,246 and a loss per share of $0.25. Cash was $1,513,550 with short-term investments of $10,195,791, and working capital of $11,587,582. The company raised about $5.3M through an at-the-market stock program and invested $2,900,000 for a 19.99% stake in America First Defense.AI LLC, while stating it expects existing liquidity to cover at least twelve months of operations.
Gaxos.ai (GXAI) reported Q3 2025 results. Revenue reached $498,271, up sharply from $2,704 a year ago, driven mainly by RNK Health’s non‑clinical patient support services. Operating expenses were $1,813,026, reflecting increased selling, general and administrative spending and continued R&D. Net loss attributable to common shareholders was $1,001,474.
For the nine months, revenue totaled $692,974. Other income contributed $173,882 in the quarter, including $156,034 of interest income. As of September 30, 2025, cash was $914,183 and short‑term investments were $12,058,377; working capital was $12,968,843. Management states existing liquidity is expected to fund operations for the next twelve months.
The company expanded its software assets, recording intangible assets, net, of $763,233 after purchasing software in February 2025 for $500,000 in cash and 200,000 shares. Common shares outstanding were 7,123,453 as of November 13, 2025.
Gaxos.ai reported initial commercial revenue while continuing product investments and recording operating losses. Revenue was $170,971 in Q2 2025 and $194,703 for the six months, driven primarily by RNK Health administrative services ($170,398 Q2; $192,950 six months). The company recorded a net loss of $824,572 for the quarter and $2,056,634 year-to-date, driven by research and development and general and administrative costs of $1,153,665 in Q2.
On the balance sheet, cash declined to $1,718,964 from $14,398,099 at December 31, 2024, after purchasing short-term investments that rose to $12,326,666. Working capital remained positive at $13,992,440, and management states these resources should be sufficient to meet operating needs for the next 12 months. The company recorded a $748,000 intangible asset acquisition funded with $500,000 cash and 200,000 shares valued at $248,000.